eligibility_summary
Adults 18–75 with MM (IMWG), ECOG 0–2, ≥12‑week life expectancy, refractory/relapsed after ≥3 lines incl PI, IMiD, and anti‑CD38, adequate counts (ALC>0.3, ANC≥0.5×10^9/L, Hgb≥60 g/L, Plt≥30×10^9/L), women negative test/use contraception. Exclude: neuro/cardiac disease (QT), pregnancy/lactation, HIV, active HBV/HCV, recent steroids/anticancer tx, poor T‑cell proliferation, renal/hepatic dysfunction (Cr>2.5, AST/ALT>3×ULN, bili>2.0), other active cancers, recent ASCT/any allo‑SCT, or investigator risk.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Trial: Phase 1, single-arm dose-escalation study in relapsed/refractory multiple myeloma testing DeepTag-GPRC5D CAR T-cells. Drug/intervention: DeepTag-GPRC5D Targeted CAR T-cells (biological, autologous cellular immunotherapy). Mechanism: Patient T cells are genetically engineered to express a chimeric antigen receptor binding GPRC5D, upon antigen engagement, CAR signaling (CD3ζ with co-stimulation) activates T cells to proliferate and kill tumor via cytotoxic granules and cytokine release. Target cells/pathways: GPRC5D-expressing malignant plasma cells in multiple myeloma, pathways include CAR-mediated T-cell activation and cytotoxicity directed at the GPRC5D antigen (an orphan GPCR enriched on myeloma cells).